Company Overview
| Parameter | Details |
|---|
| Company Name | Rubicon Research Limited |
| NSE Symbol | RUBICON |
| Sector | Pharmaceuticals |
| Industry | Specialty & Generic Formulations |
| Founded | 1999 |
| Primary Market | United States |
| Market Cap | ₹20,000+ Cr |
| Business Focus | Development, Manufacturing & Commercialization of Differentiated Formulations |
| Listing | NSE & BSE |
| Dividend Yield | Nil |
| Debt Position | Improving |
| F&O Segment | No |
Rubicon Research is a formulation-focused pharmaceutical company with a strong presence in the U.S. generic and specialty drug market. More than 99% of revenue comes from the U.S. market, making it a unique export-oriented pharma play.
Fundamental Scorecard
| Metric | Rating |
|---|
| Revenue Growth | ⭐⭐⭐⭐⭐ |
| Profit Growth | ⭐⭐⭐⭐⭐ |
| ROE | ⭐⭐⭐⭐☆ |
| ROCE | ⭐⭐⭐⭐☆ |
| Balance Sheet | ⭐⭐⭐⭐☆ |
| Cash Flow | ⭐⭐⭐⭐☆ |
| Business Visibility | ⭐⭐⭐⭐☆ |
Key Financial Metrics
| Metric | Value |
|---|
| P/E Ratio | ~86–107 |
| ROE | ~19–27% |
| ROCE | ~21–28% |
| 5-Year Profit CAGR | Strong |
| Revenue Growth FY26 | ~37% YoY |
| Promoter Holding | ~60% |
| FII Holding | ~7.5% |
| DII Holding | ~10% |
Strengths
| Strength | Impact |
|---|
| Strong U.S. Market Presence | High-margin opportunities |
| Rapid Revenue Growth | Supports earnings expansion |
| Specialty Formulation Expertise | Competitive advantage |
| Improving Debt Profile | Better financial flexibility |
| Strong Product Pipeline | Future growth visibility |
Risks
| Risk Factor | Impact |
|---|
| High Valuation | Limits margin of safety |
| Dependence on U.S. Market | Geographic concentration risk |
| Regulatory Risk | USFDA observations can impact growth |
| Customer Concentration | Large clients contribute significant revenue |
These risks are frequently highlighted by investors and analysts due to Rubicon's heavy reliance on the U.S. market and premium valuation.
Technical Screener
| Indicator | Status |
|---|
| Long-Term Trend | 🟢 Bullish |
| Revenue Momentum | Strong |
| Earnings Momentum | Strong |
| Institutional Participation | Increasing |
| Growth Stock Category | Yes |
Shareholding Pattern Snapshot
| Category | Holding |
|---|
| Promoters | ~60% |
| FIIs | ~7.5% |
| DIIs | ~10% |
| Public | ~22.5% |
Investment Suitability
| Investor Type | Suitability |
|---|
| Long-Term Growth Investors | ✅ High |
| Pharma Sector Investors | ✅ High |
| Value Investors | ⚠ Moderate |
| Dividend Investors | ❌ Low |
| Momentum Investors | ✅ High |
Overall Score
| Category | Score |
|---|
| Business Quality | 8.5/10 |
| Financial Strength | 8/10 |
| Growth Potential | 9/10 |
| Valuation Comfort | 6/10 |
| Long-Term Investment Grade | ⭐⭐⭐⭐☆ |
Verdict
Rubicon Research is emerging as a high-growth specialty pharma company with strong exposure to the lucrative U.S. market. Revenue and profit growth have been impressive, return ratios are healthy, and debt levels are improving. However, investors should monitor valuation levels and regulatory risks closely. For growth-focused investors with a 3–5 year horizon, Rubicon remains an attractive pharma stock to watch.
0 Comments